These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 33765326)

  • 1. Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer.
    Marshall CH; Tunacao J; Danda V; Tsai HL; Barber J; Gawande R; Weiss CR; Denmeade SR; Joshu C
    BJU Int; 2021 Sep; 128(3):366-373. PubMed ID: 33765326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer.
    Sheikhbahaei S; Reyes DK; Rowe SP; Pienta KJ
    Prostate; 2021 Feb; 81(2):127-134. PubMed ID: 33259087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.
    Kvorning Ternov K; Sønksen J; Fode M; Lindberg H; Kistorp CM; Bisbjerg R; Palapattu G; Østergren PB
    BMJ Open; 2019 Sep; 9(9):e030218. PubMed ID: 31511288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.
    Schweizer MT; Wang H; Luber B; Nadal R; Spitz A; Rosen DM; Cao H; Antonarakis ES; Eisenberger MA; Carducci MA; Paller C; Denmeade SR
    Prostate; 2016 Sep; 76(13):1218-26. PubMed ID: 27338150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
    Markowski MC; Wang H; Sullivan R; Rifkind I; Sinibaldi V; Schweizer MT; Teply BA; Ngomba N; Fu W; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Luo J; Antonarakis ES; Denmeade SR
    Eur Urol; 2021 May; 79(5):692-699. PubMed ID: 32624280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower pretreatment serum testosterone level predicts poor prognosis in the patients with metastatic hormone-sensitive prostate cancer undergoing androgen deprivation therapy.
    Yoshida T; Kawai T; Hagiwara K; Yanagida K; Noda M; Tokura Y; Yoshimura I; Kaneko T; Nakagawa T
    Jpn J Clin Oncol; 2024 Apr; 54(4):498-503. PubMed ID: 38251778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bipolar androgen therapy (BAT): A patient's guide.
    Denmeade S; Antonarakis ES; Markowski MC
    Prostate; 2022 May; 82(7):753-762. PubMed ID: 35357024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications.
    Kumar R; Sena LA; Denmeade SR; Kachhap S
    Nat Rev Urol; 2023 May; 20(5):265-278. PubMed ID: 36543976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bipolar androgen therapy: A novel therapeutic strategy for castration-resistant prostate cancer].
    Hu YH; Guo JC; Zhang M
    Zhonghua Nan Ke Xue; 2017 Dec; 23(12):1138-1140. PubMed ID: 29738189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia.
    Korczak J; Mardas M; Litwiniuk M; Bogdański P; Stelmach-Mardas M
    Nutrients; 2023 Mar; 15(7):. PubMed ID: 37049485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life in prostate cancer patients taking androgen deprivation therapy.
    Dacal K; Sereika SM; Greenspan SL
    J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level.
    Rouleau M; Neveu B; Caron P; Morin F; Toren P; Lacombe L; Turcotte V; Lévesque É; Guillemette C; Pouliot F
    J Urol; 2022 Dec; 208(6):1214-1225. PubMed ID: 36102111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoas mass index at the level of the third lumbar vertebra on computed tomography is a prognostic predictor for metastatic castration-sensitive prostate cancer.
    Owa S; Sasaki T; Ikadai R; Tabata Y; Takeuchi Y; Nishikawa T; Kato M; Higashi S; Sugino Y; Masui S; Nishikawa K; Inoue T
    Int J Clin Oncol; 2024 Jun; 29(6):840-846. PubMed ID: 38587577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer.
    Drazer MW; Stadler WM
    Cancer J; 2016; 22(5):330-333. PubMed ID: 27749326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.
    Dambal S; Howard LE; Allott EH; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
    J Urol; 2020 Jan; 203(1):120-127. PubMed ID: 31430247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
    Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Androgen biosynthesis in castration-resistant prostate cancer: Advances in studies].
    Chen B; Cao DH; Guo JB; Liu LR; Wei Q
    Zhonghua Nan Ke Xue; 2019 Mar; 25(3):265-271. PubMed ID: 32216246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
    Saad F; Cella D; Basch E; Hadaschik BA; Mainwaring PN; Oudard S; Graff JN; McQuarrie K; Li S; Hudgens S; Lawson J; Lopez-Gitlitz A; Yu MK; Smith MR; Small EJ
    Lancet Oncol; 2018 Oct; 19(10):1404-1416. PubMed ID: 30213449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review.
    Xiong X; Qiu S; Yi X; Xu H; Lei H; Liao D; Bai S; Peng G; Wei Q; Ai J; Yang L
    Urol Oncol; 2022 Jan; 40(1):4.e19-4.e28. PubMed ID: 34548234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.